JPMorgan Chase & Co. Reduces Stock Position in IPG Photonics Corporation $IPGP

JPMorgan Chase & Co. decreased its position in IPG Photonics Corporation (NASDAQ:IPGP) by 14.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 131,543 shares of the semiconductor company’s stock after selling 21,573 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.31% of IPG Photonics worth $10,417,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of IPGP. Lazard Asset Management LLC grew its stake in shares of IPG Photonics by 81.3% in the second quarter. Lazard Asset Management LLC now owns 1,899,461 shares of the semiconductor company’s stock worth $130,397,000 after purchasing an additional 851,869 shares during the last quarter. Dimensional Fund Advisors LP raised its position in IPG Photonics by 4.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,755,864 shares of the semiconductor company’s stock valued at $139,045,000 after purchasing an additional 68,366 shares during the last quarter. AQR Capital Management LLC lifted its holdings in IPG Photonics by 53.7% in the 2nd quarter. AQR Capital Management LLC now owns 978,577 shares of the semiconductor company’s stock worth $67,101,000 after buying an additional 341,773 shares during the period. M&G PLC lifted its holdings in IPG Photonics by 6.2% in the 3rd quarter. M&G PLC now owns 637,356 shares of the semiconductor company’s stock worth $50,351,000 after buying an additional 37,336 shares during the period. Finally, Norges Bank bought a new stake in shares of IPG Photonics in the 2nd quarter worth approximately $16,671,000. 93.79% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on IPGP shares. Roth Mkm upped their target price on IPG Photonics from $105.00 to $110.00 and gave the company a “buy” rating in a report on Tuesday, February 3rd. Raymond James Financial cut shares of IPG Photonics from a “strong-buy” rating to an “outperform” rating and lifted their price target for the company from $97.00 to $180.00 in a report on Friday, February 13th. Wall Street Zen lowered shares of IPG Photonics from a “buy” rating to a “hold” rating in a report on Sunday. Benchmark reaffirmed a “hold” rating on shares of IPG Photonics in a research report on Wednesday, December 10th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of IPG Photonics in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $131.40.

Insider Buying and Selling at IPG Photonics

In other IPG Photonics news, major shareholder Valentin Gapontsev Trust I sold 7,952 shares of the company’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $80.10, for a total value of $636,955.20. Following the sale, the insider owned 6,793,099 shares in the company, valued at approximately $544,127,229.90. This represents a 0.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Mary E. Buttarazzi sold 500 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $116.22, for a total transaction of $58,110.00. Following the transaction, the chief accounting officer directly owned 4,749 shares of the company’s stock, valued at $551,928.78. This represents a 9.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 134,617 shares of company stock valued at $10,636,883 over the last three months. 39.50% of the stock is currently owned by corporate insiders.

IPG Photonics Trading Down 2.5%

IPGP opened at $115.70 on Friday. The company has a market cap of $4.88 billion, a price-to-earnings ratio of 156.35, a price-to-earnings-growth ratio of 2.84 and a beta of 0.95. The stock has a fifty day simple moving average of $115.71 and a two-hundred day simple moving average of $92.97. IPG Photonics Corporation has a 12-month low of $48.59 and a 12-month high of $155.82.

IPG Photonics (NASDAQ:IPGP) last announced its earnings results on Thursday, February 12th. The semiconductor company reported $0.46 EPS for the quarter, beating analysts’ consensus estimates of $0.25 by $0.21. The firm had revenue of $274.47 million for the quarter, compared to analysts’ expectations of $249.58 million. IPG Photonics had a net margin of 3.10% and a return on equity of 2.89%. The company’s quarterly revenue was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.18 EPS. IPG Photonics has set its Q1 2026 guidance at 0.100-0.400 EPS. On average, analysts predict that IPG Photonics Corporation will post 1.54 EPS for the current year.

IPG Photonics Profile

IPG Photonics Corporation is a global leader in the design and manufacture of high-performance fiber lasers and amplifiers used in industrial, medical, scientific, and telecommunications applications. The company’s core products include ytterbium and erbium fiber lasers, diode lasers, and fiber amplifiers that deliver high power and efficiency for precision cutting, welding, marking, and engraving. IPG’s systems are engineered to optimize process speed, reliability, and energy consumption, making them a preferred choice for advanced manufacturing environments.

In addition to stand-alone laser sources, IPG offers turnkey laser systems and integrated solutions tailored to sectors such as automotive, electronics, aerospace, additive manufacturing, and life sciences.